Essential thrombocytosis (ET) is treated based on your individual risk of blood clots, not simply on how high your platelet count is. The cornerstone of management is figuring out which risk category you fall into, then matching treatment intensity to that risk. For some people, that means low-dose aspirin alone. For others, it means platelet-lowering medication combined with aspirin. Your age, clotting history, and the specific gene mutation driving your disease all shape the plan.
How Risk Categories Guide Treatment
ET is divided into four risk tiers, and your tier determines almost everything about your treatment. The system accounts for three variables: your age, whether you’ve had a blood clot before, and whether you carry a JAK2 mutation.
- Very low risk: Age 60 or younger, no history of blood clots, no JAK2 mutation.
- Low risk: Age 60 or younger, no clot history, but JAK2 mutation is present.
- Intermediate risk: Over age 60, no clot history, no JAK2 mutation.
- High risk: Any history of blood clots, or over age 60 with a JAK2 mutation.
People in the very low and low risk groups generally do not need platelet-lowering drugs. Those in the high risk group almost always do. The intermediate group falls in a gray zone where treatment decisions are more individualized.
Why Your Mutation Type Matters
About half of ET patients carry a JAK2 mutation, and this mutation is a well-established risk factor for clotting. The other common mutations, CALR type 1 and CALR type 2, carry meaningfully lower clot risk. Pooled data show that patients with either CALR mutation have roughly 35 to 55 percent lower odds of thrombosis compared to those with JAK2. This difference is significant enough to influence both your risk category and your aspirin dosing strategy.
A smaller number of patients carry an MPL mutation, and some have none of the three (“triple negative”). These distinctions matter because they help your hematologist tailor how aggressively to treat, even when platelet counts look similar on paper.
Aspirin: More Nuanced Than It Sounds
Low-dose aspirin is the backbone of ET management across most risk levels, but the dosing schedule is not one-size-fits-all. In ET, the body produces platelets faster than normal, which means aspirin’s clot-blocking effect wears off more quickly. Twice-daily dosing suppresses platelet activation more consistently than once daily, and plain aspirin is absorbed better than enteric-coated formulations for this purpose.
Current expert practice favors twice-daily aspirin for JAK2-mutated patients in the low risk group and for MPL or CALR type 1 patients who have cardiovascular risk factors or microvascular symptoms like burning in the hands and feet. Once-daily dosing is typically adequate for patients already taking a platelet-lowering drug, because the medication itself slows platelet production enough to keep aspirin’s effect from fading between doses. In high-risk patients with recurrent arterial clots or persistent symptoms despite treatment, twice-daily dosing may still be considered on top of cytoreductive therapy.
One important caveat: when platelet counts are extremely high (generally above 1 million or so), aspirin can paradoxically increase bleeding risk rather than prevent clots. In those situations, aspirin may be held until counts come down with treatment.
Platelet-Lowering Therapy for High-Risk Patients
If you’re classified as high risk, the standard first-line treatment is hydroxyurea combined with once-daily aspirin. The evidence behind this pairing is strong. In a landmark randomized trial comparing hydroxyurea to no platelet-lowering treatment in high-risk patients, the thrombosis rate dropped from 24 percent to 3.6 percent. The typical goal is to bring your platelet count below 600,000 per microliter.
Hydroxyurea is taken as a daily oral capsule, and the dose is adjusted over weeks to months based on your blood counts. You’ll need regular blood work, especially early on, to make sure counts come down without dropping too low. Most people tolerate it well, though some develop mouth sores, skin changes, or leg ulcers that may prompt a switch to a different drug.
Pegylated Interferon
Pegylated interferon is the main alternative, used either as a second-line option when hydroxyurea isn’t tolerated or, increasingly, as a first-line choice in younger patients. It’s given as a weekly injection under the skin. In a study following 40 ET patients for a median of seven years, 80 percent achieved a hematologic response, meaning their blood counts normalized. Some patients also saw a reduction in the size of their mutant cell population, a so-called molecular response, though this was less common (about 37 percent in ET).
The starting dose has been lowered over the years due to side effects. Early trials began at much higher doses but had to scale back because of toxicity. Current expert recommendations suggest starting at a low dose and increasing gradually. Side effects can include fatigue, flu-like symptoms, mood changes, and liver inflammation, so close monitoring is important, especially in the first few months.
Anagrelide
Anagrelide is another platelet-lowering option, FDA-approved specifically for thrombocytosis in myeloproliferative neoplasms. It works differently from hydroxyurea, targeting platelet production more selectively. The main concern with anagrelide is its effect on the heart. Before starting it, you’ll need an ECG, and your doctor will monitor for palpitations, rapid heartbeat, or fluid retention throughout treatment. It should not be used in people with a history of heart rhythm problems, particularly conditions that prolong the QT interval on an ECG. If you notice chest pain, palpitations, or an irregular heartbeat while taking it, that warrants immediate medical attention.
Managing Microvascular Symptoms
Many ET patients experience symptoms driven by abnormal blood flow in small vessels. The most distinctive is erythromelalgia, a condition causing intense burning pain, redness, and warmth in the hands or feet. It can be dramatic and debilitating, but it often responds remarkably well to aspirin. Standard treatment for erythromelalgia in ET ranges from 325 to 650 mg of aspirin per day, though once the condition is controlled, a regular low dose (around 100 mg daily) can maintain relief. Other microvascular symptoms like headaches, visual disturbances, lightheadedness, and tingling also tend to improve with aspirin and, when needed, platelet-lowering therapy.
Treatment During Pregnancy
ET raises specific concerns during pregnancy because of increased risks of miscarriage, placental problems, and clotting. The approach depends on whether the pregnancy is considered high risk, which accounts for prior pregnancy complications, clot history, and mutation status.
Low-dose aspirin (once daily) is recommended for high-risk pregnancies. Hydroxyurea is stopped before conception because it can harm the developing fetus. If platelet-lowering treatment is needed during pregnancy, interferon is the drug of choice, as it has the most reassuring safety profile in this setting. In a study of 34 high-risk ET pregnancies treated with interferon, the drug was combined with aspirin and/or a blood-thinning injection in most cases. The combination of aspirin plus a blood thinner resulted in live births in all 14 pregnancies where it was used.
The typical protocol calls for stopping aspirin about two to four weeks before a planned delivery and switching to injectable blood thinner around that time. After delivery, the blood thinner is continued for six weeks postpartum to cover the period when clotting risk is naturally elevated. For women with a history of clots or prior pregnancy loss, using the blood thinner throughout the entire pregnancy is sometimes recommended, though the evidence for this is less definitive.
What Treatment Looks Like Day to Day
For most people with ET, treatment is not intensive. If you’re in a lower risk category, you may take aspirin and see your hematologist every few months for blood counts. If you’re on hydroxyurea, visits are more frequent at first while your dose is being adjusted, then typically every three to four months once things stabilize. The platelet count target of under 600,000 is a useful benchmark, but your doctor will also pay attention to your white blood cell count, hemoglobin, and how you’re feeling overall.
ET is a chronic condition, and most people live with it for decades. The treatment goal isn’t to cure the disease but to prevent its most dangerous complication: blood clots in arteries or veins. A small percentage of patients will eventually see their disease transform into a more aggressive bone marrow condition, and your hematologist will watch for signs of that over time through periodic blood work and, occasionally, repeat bone marrow biopsies.